ClinicalTrials.gg
RecruitingNCT05511363Updated Aug 17, 2026

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)

A Phase 3 interventional study of KarXT and Placebo in Psychosis Associated With Alzheimer's Disease, sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company. Recruiting at 129 sites in 13 countries. Open to participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2022; still recruiting 4 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
410
Allocation
Randomized
Ages
55 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies testing xanomeline in Alzheimer Disease — 10 open to participants now, 10 under way, 10 of them phase 3. xanomeline · Alzheimer Disease.

Planned enrollment
8th of 10
410 · median 463
Started
2022
the only one that year
Phase 3
10 of 10
10 open now
Registered
1st of 10
by date
Lead sponsor
4 of 10
Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Among the 10 studies testing xanomeline in Alzheimer Disease, this one is the 8th largest by planned enrollment, is the only one that started in 2022, is one of 10 in phase 3, and was the 1st registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

10 of the 10 studies testing xanomeline in Alzheimer Disease are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About xanomeline

xanomeline: first FDA approval 2024 (COBENFY). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 55 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing xanomeline in Alzheimer Disease, or all of them as a file.
02

Study summary

This is a Phase 3, 38-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with psychosis associated with Alzheimer's Disease.

The primary objective of the study is to evaluate relapse prevention in subjects with psychosis associated with Alzheimer's Disease treated with KarXT compared to placebo. The secondary objectives of the study are to evaluate the time from randomization to discontinuation for any reason or relapse and safety and tolerability in subjects with psychosis associated with Alzheimer's Disease treated with KarXT compared to placebo.

03

Conditions studied

  • Psychosis Associated With Alzheimer's Disease

Browse trials for

04

Who can participate

Ages eligible
55 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is aged 55 to 90 years, inclusive, at Screening
  • Can understand the nature of the study and protocol requirements and provide a signed form before any study assessments are performed. If the subject is deemed not competent to provide consent, the following requirements for consent must be met.

    i) The subject's legally acceptable representative must provide informed consent; ii) The subject must provide assent or similar where permitted per local law/regulation and as approved by the IRB/IEC.

  • Meets clinical criteria for possible or probable Alzheimer's Disease
  • Has a Magnetic Resonance Imaging (MRI) or Computed Tomography (CT) scan of the brain (completed within the past 5 years) taken during or subsequent to the onset of dementia to rule out other central nervous system (CNS) disease that could account for the dementia syndrome. If not available, a non-contrast brain MRI or non-contrast head CT must be done during screening.
  • Living at the same location for a minimum of 4 weeks before Screening, with the intention of living at the same location throughout the study.
  • Capable of self-locomotion (alone or with the aid of an assistive device) and have an identified caregiver or study partner who, in the investigator's judgment, has frequent and sufficient contact with the participant (ie, ≥ approximately 7 hours per week) on a regular basis to reliably provide accurate information regarding the participant's cognitive, behavioral, and functional status, and is willing to:

    i) Attend all visits and report on participant's status. ii) Oversee participant compliance with medication and study procedures; iii) Participate in the study assessments and provide informed consent to participate in the study.

  • History of psychotic symptoms (meeting International Psychogeriatric Association [IPA] criteria) for at least 2 months prior to Screening.
  • Clinical Global Impressions-Severity (CGI-S) scale with a score ≥4 (moderate) at Screening and Baseline. CGI-S requires the assessor to consider aspects of the psychosis prior to providing a global assessment of severity. These aspects include hallucinations and delusions.
  • Subjects are required to meet at least one of the following criteria at Screening and Baseline:

    i) Moderate to severe delusions, defined as Neuropsychiatric Inventory-Clinician (NPI-C): Delusions domain score of ≥2 on two of the eight items OR; ii) Moderate to severe hallucinations, defined as NPI-C: Hallucinations domain score of ≥ 2 on two of the seven items.

  • (MMSE) score of 6 to 24, inclusive, at Screening
  • If the subject is taking a cholinesterase inhibitor and/or memantine, they must have been on a stable dose for 6 weeks prior to Screening and be willing to maintain a stable dose for the duration of the study.
  • Participant is willing and able to attend the study visit for the study duration, follow instructions, and comply with the protocol requirements
  • must be within 16 to 40 kg/m2 and participants with a BMI of 16 to \<18 kg/m2 must have a body weight ≥40 kg.
  • A female (as assigned at birth) is eligible to participate if she is not pregnant or breastfeeding. Individual of (IOCBP) must be able and willing to use at least 1 highly effective method of during the study and for at least 1 menstrual cycle (e.g., 30 days) after the last dose of IMP.

Exclusion criteria

Exclusion Criteria:

  • Psychotic symptoms that are primarily attributable to a condition other than the Alzheimer's Disease causing dementia
  • History of major depressive episode with psychotic features during the 12 months prior to Screening
  • History of a diagnosis of bipolar disorder, schizophrenia, or schizoaffective disorder
  • Significant or severe medical conditions including pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, cardiovascular or oncologic disease, or any other condition that, in the opinion of the Investigator, could jeopardize the safety of the subject, ability to complete or comply with the study procedures or validity of the study results
  • Significant or severe renal impairment based on a screening cutoff for Estimated (eGFR) of \<50 mL/min
  • History of ischemic stroke within 12 months prior to Screening or any evidence of hemorrhagic stroke
  • History of cerebral amyloid angiopathy, epilepsy, central nervous system neoplasm, unstable thyroid function, or unexplained syncope
  • Any of the following:

    i) Class 2 congestive heart failure; ii) Grade 2 or greater angina pectoris; iii) Sustained ventricular tachycardia; iv) Ventricular fibrillation; v) Torsade de pointes; vi) Implantable cardiac defibrillator.

  • Myocardial infarction within the 6 months prior to Screening
  • Personal or family history of symptoms of long syndrome as evaluated by the investigator
  • , cirrhosis, biliary duct abnormalities, active biliary disease, hepatobiliary carcinoma, and/or active hepatic viral infections as indicated by medical history or liver function tests results
  • History or high risk of urinary retention, gastric retention, or narrow-angle glaucoma as evaluated by the investigator
  • Participants with any of the following:

    i) History of bladder stones; ii) History of recurrent urinary tract infections; iii) For male participants:

    1. Serum prostate specific antigen (PSA) > 10 ng/mL at Screening
    2. An IPSS of 5 (almost always) on items 1, 3, 5, or 6
    3. A sum of scores on IPSS items 1, 3, 5, and 6 of ≥9
  • History of obstructive gastrointestinal disorder, gastric retention, irritable bowel syndrome (with or without constipation) or serious constipation requiring treatment within the last 6 months
  • Risk of suicidal behavior during the study as determined by clinical assessment and/ or C-SSRS
  • abnormal finding on the physical examination, , or clinical laboratory results at Screening
  • Urine toxicology screen is positive substances other than cannabis or benzodiazepines (both cannabis and short-or medium-acting benzodiazepines are allowed in limited quantities during the study) unless approval has been given by the Medical Monitor
  • Currently receiving monoamine oxidase inhibitors, anticonvulsants (e.g., lamotrigine, divalproex), mood stabilizers (eg, lithium) tricyclic antidepressants (e.g., imipramine, desipramine), or any other psychoactive medications except for as-needed anxiolytics (e.g., lorazepam) and unable to complete the :

    i) Selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors taken at a stable dose for at least 8 weeks prior to Screening may be permitted; ii) Mirtazapine or trazodone may be used if started at least 8 weeks prior to Screening. If needed, an extension (up to two weeks) of the Screening Period may be allowed with approval of the Sponsor/Medical Monitor.

  • If, in the opinion of the Investigator and/or Sponsor/Medical Monitor, subject is unsuitable for enrollment in the study or subject has any finding that, in the view of the Investigator and/or Sponsor/ Medical Monitor, may compromise the safety of the subject or affect his/her ability to adhere to the protocol visit schedule or fulfill visit requirements
  • Positive test for coronavirus (COVID-19) within 2 weeks before or at Screening; antigen or PCR local testing can be done at the discretion of the Investigator
  • Unable to taper and discontinue a concomitant medication that would preclude participation in the study
  • Prior exposure to KarXT
  • Experienced any significant adverse events due to trospium, including a known to trospium
  • Participation in another clinical study in which the subject received an experimental or drug within 3 months before Screening or has participated in more than 2 clinical studies in the past year
  • Other protocol-defined Inclusion/Exclusion criteria apply
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
410 participants (estimated)

Study arms

  • Experimental
    KarXT

    Xanomeline and Trospium Chloride Capsules

    Drug: KarXT

  • Placebo comparator
    Placebo

    Placebo Capsules

    Drug: Placebo

Interventions

  • DrugKarXT

    Drug pages: Xanomeline · Trospium

    KarXT 20 mg/2 mg TID KarXT 30 mg/3 mg TID KarXT 40 mg/4 mg TID KarXT 50 mg/5 mg TID KarXT 66.7/6.67 mg TID

  • DrugPlacebo

    Placebo Capsules

06

What researchers measure

Primary outcomes

  1. Time from randomization to relapse

    Time frame: Week 38

Secondary outcomes

  1. Time from randomization to first occurrence of treatment discontinuation for any reason or relapse

    Time frame: Week 38

  2. Change in NPI-C: H+D Caregiver Observed Frequency x Severity Score (NPI-C: H+D CObs)

    Time frame: Up to approximately Week 38

  3. Change in Neuropsychiatric Inventory-Clinician rating scale (NPI-C) Core score Caregiver Distress scale

    NPI-C Core score includes assessment for hallucinations, delusions, agitation, and aggression domains.

    Time frame: Up to approximately Week 38

  4. Number of participants with Adverse Events (AEs)

    Time frame: Up to approximately Week 42

  5. Number of participants with Treatment Emergent Adverse Events (TEAEs)

    Time frame: Up to approximately Week 42

  6. Number of participants with Serious Adverse Events (SAEs)

    Time frame: Up to approximately Week 42

  7. Number of participants with TEAEs leading to study withdrawal

    Time frame: Up to approximately Week 42

  8. Number of participants with AEs including procholinergic and anticholinergic symptoms

    Procholinergic symptoms include nausea, vomiting, and diarrhea and anticholinergic symptoms include dry mouth, constipation, urinary retention and blurred vision.

    Time frame: Up to approximately Week 42

  9. Number of participants with Adverse Events of Special Interest (AESIs)

    AESIs include symptomatic orthostasis, syncope, urinary adverse events, and elevated liver enzymes.

    Time frame: Up to approximately Week 42

  10. Barnes Akathisia Rating Scale (BARS)

    Time frame: Up to approximately Week 38

  11. Abnormal Involuntary Movement Scale (AIMS)

    Time frame: Up to approximately Week 38

  12. Body weight

    Time frame: Up to approximately Week 38

  13. BMI

    Time frame: Up to approximately Week 38

  14. Number of participants with clinically significant orthostatic vital signs

    Time frame: Up to approximately Week 38

  15. Number of participants with clinically significant laboratory evaluations

    Laboratory evaluations include hematology, clinical chemistry, coagulation, prolactin levels, and urinalysis

    Time frame: Up to approximately Week 38

  16. Number of participants with clinically significant 12-lead electrocardiogram (12-lead ECG)

    Time frame: Up to approximately Week 38

  17. Number of participants with suicidal ideation as assessed using the Columbia-Suicide Severity Rating Scale (C-SSRS)

    Time frame: Up to approximately Week 38

  18. Assessment of cognition as measured by Mini-Mental State Examination (MMSE)

    Time frame: Up to approximately Week 38

  19. International Prostate Symptom Score (IPSS) (males only)

    Time frame: Up to approximately Week 38

07

Study locations

36 of 129 sites recruiting
  • Local Institution - 1029
    Homewood, Alabama 35209-6809, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1044
    Phoenix, Arizona 85012-2836, United States
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 1033
    Encino, California 91436-2201, United States
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 1031
    Irvine, California 92612-1246, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • ATP Clinical Research-302 W La Veta Ave
    Orange, California 92866, United States
    Recruiting
    • Gustavo Alva, Site 1001 · Contact949-354-5353
  • Local Institution - 1043
    Pasadena, California 91106, United States
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 1047
    San Marcos, California 92069-3595, United States
    Completed

    Not enrolling at this site — choose another above.

  • Sunwise Clinical Research, LLC - Walnut Creek - IVY - PPDS
    Walnut Creek, California 94596, United States
    Recruiting
    • Ira Glick, Site 1007 · Contact925-298-5147
  • Local Institution - 1014
    Colorado Springs, Colorado 80907-5302, United States
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 1013
    Stamford, Connecticut 06905-1206, United States
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 1011
    Boca Raton, Florida 33487-2768, United States
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 1020
    Bonita Springs, Florida 34134, United States
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 1015
    Bradenton, Florida 34209-4687, United States
    Completed

    Not enrolling at this site — choose another above.

  • K2 Medical Research - Winter Garden
    Clermont, Florida 34711-5933, United States
    Recruiting
    • Christopher Galloway, Site 1048 · Contact321-500-5252
  • Arrow Clinical Trials
    Daytona Beach, Florida 32117-5532, United States
    Recruiting
    • David Billmeier, Site 1023 · Contact386-278-8000
  • Local Institution - 1045
    Doral, Florida 33172-2638, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1046
    Hialeah, Florida 33012-5826, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1024
    Hialeah, Florida 33012-5884, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 1052
    Hialeah, Florida 33012, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1049
    Homestead, Florida 33032, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • K2 Medical Research - Maitland
    Maitland, Florida 32751-5669, United States
    Recruiting
    • Brandon Lenox, Site 1039 · Contact407-670-5833
  • Local Institution - 1021
    Miami, Florida 33122-1335, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1005
    Miami, Florida 33125-3724, United States
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 1115
    Miami, Florida 33135, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1010
    Miami, Florida 33137, United States
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 1143
    Miami, Florida 33145-2455, United States
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 1009
    Miami, Florida 33155-4630, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1129
    Miami, Florida 33165-3947, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1053
    Miami, Florida 33166, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1006
    Miami, Florida 33173-1474, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1111
    Miami, Florida 33173, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1054
    Miami, Florida 33186-4643, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1042
    Miami, Florida 33186-5882, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1032
    Miami Lakes, Florida 33014-5602, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1026
    Miami Springs, Florida 33166-5260, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1027
    Ocala, Florida 34470-6657, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 1012
    Pensacola, Florida 32504-8608, United States
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 1008
    St. Petersburg, Florida 33713-8844, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University of South Florida
    Tampa, Florida 33606, United States
    Recruiting
    • Mark Kindy, Site 1050 · Contact813-972-2000
  • Local Institution - 1041
    Tampa, Florida 33607-4629, United States
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 1040
    The Villages, Florida 32159-8986, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 1037
    Chicago, Illinois 60623, United States
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 1018
    Manhasset, New York 11030-3816, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1-14IL3BJP
    New York, New York 10003-1759, United States
    Not yet recruiting
    • Site 1-14IL3BJP · Contact
  • Local Institution - 1030
    New York, New York 10016, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 1051
    New York, New York 10032-3720, United States
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 1017
    New York, New York 10032, United States
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 1002
    Staten Island, New York 10314-1607, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 1034
    Stony Brook, New York 11794-0001, United States
    Completed

    Not enrolling at this site — choose another above.

  • Five Towns Neurology, PC
    Woodmere, New York 11598-1739, United States
    Recruiting
    • David Steiner, Site 1025 · Contact516-239-1800
  • Local Institution - 1003
    Canton, Ohio 44718, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 1028
    Oklahoma City, Oklahoma 73104-5007, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 1016
    Oklahoma City, Oklahoma 73112, United States
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 1019
    Allentown, Pennsylvania 18103, United States
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 1035
    Charleston, South Carolina 29425-8900, United States
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 1038
    Franklin, Tennessee 37067-5922, United States
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 1022
    Flower Mound, Texas 75028-2011, United States
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 1036
    Frisco, Texas 75034-6262, United States
    Completed

    Not enrolling at this site — choose another above.

  • Clinical Trial Network - 7080 Southwest Fwy
    Houston, Texas 77074-2085, United States
    Recruiting
    • Djamchid Lotfi, Site 1004 · Contact713-484-6947
  • Local Institution - 4505
    Sofia, Sofia-Grad 1431, Bulgaria
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 4502
    Sofia, Sofia-Grad 1510, Bulgaria
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 4506
    Cherven Bryag, 5980, Bulgaria
    Not yet recruiting
    • Site 4506 · Contact
  • Medical Center Medconsult Pleven OOD
    Pleven, 5800, Bulgaria
    Recruiting
    • Maria Aleksandrova, Site 4503 · Contact+35964910999
  • Medical Center Sveti Naum EOOD
    Sofia, 1113, Bulgaria
    Recruiting
    • Assen Karadaliev, Site 4501 · Contact+359888220704
  • Local Institution - 1-14IBHZ4D
    Stara Zagora, 6003, Bulgaria
    Not yet recruiting
    • Site 1-14IBHZ4D · Contact
  • Local Institution - 4504
    Vratsa, 3000, Bulgaria
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 1-14JRHMIY
    Zagreb, City of Zagreb 10000, Croatia
    Not yet recruiting
    • Site 1-14JRHMIY · Contact
  • Local Institution - 4103
    Zagreb, City of Zagreb 10000, Croatia
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 4105
    Zagreb, City of Zagreb 10000, Croatia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Polyclinic Neuron
    Zagreb, City of Zagreb 10000, Croatia
    Recruiting
    • Neven Henigsberg, Site 4102 · Contact+38514596866
  • Local Institution - 4101
    Zagreb, City of Zagreb 10090, Croatia
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Psychiatric Clinic Sveti Ivan
    Zagreb, City of Zagreb 10090, Croatia
    Recruiting
    • Igor Filipcic, Site 4104 · Contact38513430020
  • CLINTRIAL s.r.o.
    Prague, Praha, Hlavní Mesto 100 00, Czechia
    Recruiting
    • Zdenek Solle, Site 4002 · Contact+420222510607
  • Local Institution - 4003
    Brno, South Moravian 628 00, Czechia
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 4001
    Kutná Hora, 284 01, Czechia
    Completed

    Not enrolling at this site — choose another above.

  • A-SHINE s.r.o.
    Pilsen, 301 00, Czechia
    Recruiting
    • Lubos Janu, Site 4005 · Contact420777242101
  • Local Institution - 1-14IL3BFV
    Prague, 109 00, Czechia
    Not yet recruiting
    • Site 1-14IL3BFV · Contact
  • Local Institution - 4004
    Prague, 140 00, Czechia
    Completed

    Not enrolling at this site — choose another above.

  • Vestra Clinics s.r.o.
    Rychnov nad Kněžnou, 516 01, Czechia
    Recruiting
    • Ladislav Pazdera, Site 4006 · Contact420604236033
  • CHU de Reims Hôpital Robert Debré
    Reims, Marne 51100, France
    Recruiting
    • Jean Luc Novella, Site 2501 · Contact+33326784410
  • Local Institution - 1-14ILFZ33
    Villeurbanne, Rhône 69100, France
    Not yet recruiting
    • Site 1-14ILFZ33 · Contact
  • Local Institution - 2502
    Dijon, 21079, France
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 2503
    Rouen, 76000, France
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 2401
    Böblingen, Baden-Wurttemberg 71034, Germany
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 2403
    Bayreuth, Bavaria 95445, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 2402
    Homburg, Saarland 66424, Germany
    Withdrawn

    Not enrolling at this site — choose another above.

  • Local Institution - 1-14IL3BK3
    Ahmedabad, Gujarat 380061, India
    Not yet recruiting
    • Site 1-14IL3BK3 · Contact
  • Local Institution - 1-14IW4MUN
    New Delhi, National Capital Territory of Delhi 110029, India
    Not yet recruiting
    • Site 1-14IW4MUN · Contact
  • Local Institution - 1-14IW4MT8
    Hyderabad, 500034, India
    Not yet recruiting
    • Site 1-14IW4MT8 · Contact
  • Local Institution - 1-14ILFYZQ
    Salerno, Campania 84131, Italy
    Not yet recruiting
    • Site 1-14ILFYZQ · Contact
  • Local Institution - 2301
    Rome, Lazio 00179, Italy
    Completed

    Not enrolling at this site — choose another above.

  • Azienda Ospedaliero-Universitaria di Modena - Policlinico di Modena
    Baggiovara, Modena 41126, Italy
    Recruiting
    • Giovanna Zamboni, Site 2306 · Contact+390593962201
  • Local Institution - 2307
    Ponderano (Biella), Piedmont 13875, Italy
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Local Institution - 2308
    Florence, Tuscany 50139, Italy
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 2304
    Milan, 20121, Italy
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 2305
    Monza, 20900, Italy
    Completed

    Not enrolling at this site — choose another above.

  • Local Institution - 2302
    Pisa, 56126, Italy
    Completed

    Not enrolling at this site — choose another above.

  • Fondazione Policlinico Universitario A Gemelli - Rome - PPDS
    Roma, 00168, Italy
    Recruiting
    • Camillo Marra, Site 2303 · Contact+390630154333
  • Local Institution - 2309
    Roma, 00189, Italy
    Completed

    Not enrolling at this site — choose another above.

  • University Clinical Center of Serbia - Pasterova 2 - PPDS
    Belgrade, Belgrade 11000, Serbia
    Recruiting
    • Tanja Stojkovic, Site 4302 · Contact381607545958

Showing the first 100 of 129 sites across 13 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Oct 2026, 49 months after the start.

Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's planned 49 months is above that.

Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2022
First posted
Aug 23, 2022
StartActual
Aug 23, 2022
Primary completionEst.
Oct 5, 2026
CompletionEst.
Oct 5, 2026
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05511363
Responsible party
Sponsor
First posted
Aug 23, 2022
Start date
Aug 23, 2022
Primary completion
Oct 5, 2026 (estimated)
Completion
Oct 5, 2026 (estimated)
Last update
Aug 17, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Xanomeline · Trospium

Start the discussion